Research Library

Each year, millions of people migrate within and beyond their own countries because of rising temperatures and weather-related disasters. This new policy brief on climate-induced displacement from the Edward P. Djerejian Center for the Middle East explains the term “climate mobility,” distinguishes between voluntary and forced migration, and explores the challenges and opportunities presented by this reality of our times.

In 2026, the USMCA will undergo an open-ended review that could result in anything from minor changes to significant renegotiations. Nonresident fellow Simon Lester discusses this unprecedented process and argues that the U.S. and Mexico must follow Canada’s lead in starting preparations.

From 2020 to 2023, sales of hemp-derived cannabinoids increased by 1,283%, reaching a value of $2.78 billion last year. Although the Texas hemp industry is booming, lack of regulation poses risks to public health. A new brief from the Drug Policy Program makes specific recommendations for strengthening and enforcing current laws — ensuring consumer safety while also providing economic benefits for the state.

No longer confined to the lab, genetically altered products are now being marketed to the public. This means the need for genetic biocontainment has shifted from the laboratory to the general environment.

Recent federal research security initiatives have put the U.S. at risk of losing its lead in science and technology, write senior fellow Neal F. Lane, Steven Pei, and Jeremy Wu. They lay out a path toward clear, fair policy that safeguards America’s security and competitiveness while fostering a welcoming research environment for foreign talent.

While the U.S. has tried to appear assertive in taking action against China’s trade practices, this strategy has yielded limited results. In a new commentary, fellow Simon Lester summarizes current U.S. policies addressing China’s trade conduct and advocates for the U.S.’ revitalized engagement with the World Trade Organization’s dispute settlement system.

The safety and efficacy of many stem cell treatments remain unproven by the FDA, yet state laws promote access and use of these unchecked and potentially harmful treatments. Fellow Kirstin R.W. Matthews summarizes her recent publication in a new commentary — outlining public health consequences of these state laws and calling for scientific societies’ advocacy in state policymaking.